CD8 + T-cell Immune Evasion Enables Oncolytic Virus Immunotherapy

EBioMedicine

Volumn 5, Issue , 2016, Pages 59-67

  Pourchet, Aldo ^a   Fuhrmann, Steven R ^b   Pilones, Karsten A ^a,c   Demaria, Sandra ^a,c   Frey, Alan B ^a   Mulvey, Matthew ^b   Mohr, Ian ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Benevir Biopharm   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

CD8 + T cell immune evasion; Immunotherapy; Oncolytic virus; TAP inhibitor

Indexed keywords

GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; ONCOLYTIC VIRUS; PLASMID DNA; ICP47 PROTEIN, HERPES SIMPLEX VIRUS; IMMEDIATE EARLY PROTEIN; UL49.5 PROTEIN, BOVINE HERPESVIRUS TYPE 1; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER CELL LINE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOPATHOGENIC EFFECT; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; HERPES SIMPLEX VIRUS 1; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; IMMUNE EVASION; INNATE IMMUNITY; LUNG METASTASIS; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; SPLEEN CELL; TUMOR VOLUME; TUMOR XENOGRAFT; VERO CELL LINE; VIRUS PLAQUE; ANIMAL; BLADDER TUMOR; BOVINE; BREAST TUMOR; DISEASE MODEL; GENETICS; HUMAN ALPHAHERPESVIRUS 1; IMMUNOLOGY; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CATTLE; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; HERPESVIRUS 1, HUMAN; HUMANS; IMMEDIATE-EARLY PROTEINS; IMMUNE EVASION; MICE; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; URINARY BLADDER NEOPLASMS; VIRAL ENVELOPE PROTEINS;

EID: 84955618101     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2016.01.022     Document Type: Article

References (55)

1. Ahn K., et al. Molecular mechanism and species specificity of TAP inhibition by herpes simplex virus ICP47. EMBO J. 1996, 15:3247-3255.
2. Altomonte J., et al. Enhanced oncolytic potency of vesicular stomatitis virus through vector-mediated inhibition of NK and NKT cells. Cancer Gene Ther. 2009, 16:266-278.
3. Andtbacka R.H., et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J. Clin. Oncol. 2015, 33:2780-2788.
4. Aslakson C.J., Miller F.R. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 1992, 52:1399-1405.
5. Bell J., McFadden G. Viruses for tumor therapy. Cell Host Microbe 2014, 15:260-265.
6. Brown M.C., et al. Oncolytic polio virotherapy of cancer. Cancer 2014, 10.1002/cncr.28862.
7. Chahlavi A., Rabkin S.D., Todo T., Sundaresan P., Martuza R.L. Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice. Gene Ther. 1999, 6:1751-1758.
8. Chiocca E.A., Rabkin S.B. Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol. Res. 2014, 2:295-300.
9. Chou J., Kern E.R., Whitley R.J., Roizman B. Mapping of herpes simplex virus-1 neurovirulence to gamma (1) 34.5, a gene nonessential for growth in culture. Science 1990, 250:1262-1266.
10. Demaria S., et al. Immune-mediated inhibition of metastases after treatment with local radiation and ctla-4 blockade in a mouse model of breast cancer. Clin. Cancer Res. 2005, 11:728-734.
11. Dharmadhikari N., Mehnert J.M., Kaufman H.L. Oncolytic virus immunotherapy for melanoma. Curr. Treat. Options in Oncol. 2015, 16(3):326.
12. Dolgin E. Oncolytic viruses get a boost with first FDA-approval recommendation. Nat. Rev. Drug Discov. 2015, 14:369-371.
13. Früh K., et al. A viral inhibitor of peptide transporters for antigen presentation. Nature 1995, 375:415-418.
14. Fulci G., et al. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:12873-12878.
15. Goins W.F., et al. Construction of replication-defective herpes simplex virus vectors. Curr. Protoc. Hum. Genet. 2002, 12.11.1-12.11.30.
16. + T cells is critical for superinfection by cytomegalovirus. Science 2010, 328:102-106.
17. Haralambieva I., et al. Engineering oncolytic measles virus to circum-vent the intracellular innate immune response. Mol. Ther. 2007, 15:588-597.
18. Harrington K.J., et al. Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin. Cancer Res. 2010, 16:4005-4015.
19. He B., et al. Suppression of the phenotype of 134.5 herpes simplex virus type 1: Failure of activated RNA-dependent protein kinase to Shut off protein synthesis is associated with a deletion in the domain of the 47 gene. J. Virol. 1997, 71:6049-6054.
20. Hill A., et al. Herpes simplex virus turns off the TAP to evade host immunity. Nature 1995, 375:411-415.
21. Hu J.C., et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin. Cancer Res. 2006, 12:6737-6747.
22. Ikeda K., et al. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat. Med. 1999, 5:881-887.
23. Kaufman H.L., Kohlhapp F.J., Zloza A. Oncolytic viruses: a new class of immunotherapeutic drugs. Nat. Rev. Drug Discov. 2015, 14:642-662.
24. Kilkenny C., Browne W.J., Cuthill I.C., Emerson M., Altman D.G. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 2010, 8(6):e1000412.
25. Koelle D.M., et al. Herpes simplex virus infection of human fibroblasts and keratinocytes inhibits recognition by cloned CD8+ cytotoxic T lymphocytes. J. Clin. Invest. 1993, 91:961-968.
26. Koppers-Lalic D., et al. Varicelloviruses avoid T cell recognition by UL49.5-mediated inactivation of the transporter associated with antigen processing. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:5144-5149.
27. + T cell responses against TAP-inhibited cells are readily detected in the human population. J. Immunol. 2010, 185:6508-6517.
28. Le Bœuf F., et al. Model-based rational design of an oncolytic virus with improved therapeutic Potential. Nat. Commun. 2013, 4:1974.
29. Leone P., et al. MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells. J. Natl. Cancer Inst. 2013, 105:1172-1187.
30. Lichty B.D., Breitbach C.J., Stojdl D.F., Bell J.C. Going viral with cancer immunotherapy. Nat. Rev. Cancer 2014, 14:559-567.
31. Liu B.L., et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 2003, 10:292-303.
32. Liu T.-C., Galanis E., Kirn D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat. Clin. Pract. Oncol. 2007, 4:101-117.
33. Loch S., Klauschies F., Schölz C., Verweij M.C., Wiertz E.J., Koch J., Tampé R. Signaling of a varicelloviral factor across the endoplasmic reticulum membrane induces destruction of the peptide-loading complex and immune evasion. J. Biol. Chem. 2008, 283:13428-13436.
34. Markert J.M., et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther. 2000, 7:867-874.
35. Mohr I., Gluzman Y. A herpesvirus genetic element which affects translation in the absence of the viral GADD34 function. EMBO J. 1996, 15:4759-4766.
36. Mohr I., et al. A herpes simplex virus type 1 gamma34.5 second-site suppressor mutant that exhibits enhanced growth in cultured glioblastoma cells is severely attenuated in animals. J. Virol. 2001, 75:5189-5196.
37. Mulvey M., Poppers J., Ladd A., Mohr I. A herpesvirus ribosome-associated, RNA-binding protein confers a growth advantage upon mutants deficient in a GADD34-related function. J. Virol. 1999, 73:3375-3385.
38. Mulvey M., Camarena V., Mohr I. Full resistance of herpes simplex virus type 1-infected primary human cells to alpha interferon requires both the Us11 and gamma(1)34.5 gene products. J. Virol. 2004, 78:10193-10196.
39. Nguyên T.L., et al. Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:14981-14986.
40. Oliveira C.C., van Hall T. Importance of TAP-independent processing pathways. Mol. Immunol. 2013, 55:113-116.
41. Posvad C.M., Rosenthal K.L. Herpes simplex virus-infected human fibroblasts are resistant to and inhibit cytotoxic T-lymphocyte activity. J. Virol. 1992, 66:6264-6272.
42. Rampling R., et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther. 2000, 7:859-866.
43. Senzer N.N., et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J. Clin. Oncol. 2009, 27:5763-5771.
44. Taneja S., MacGregor J., Markus S., Ha S., Mohr I. Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:8804-8808.
45. Toda M., Rabkin S.D., Kojima H., Martuza R.L. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum. Gene Ther. 1999, 10:385-393.
46. Todo T., Martuza R.L., Rabkin S.D., Johnson P.A. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:6396-6401.
47. Tomazin R., et al. Stable binding of the herpes simplex virus ICP47 protein to the peptide binding site of TAP. EMBO J. 1996, 15:3256-3266.
48. van Hall T., et al. Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants. Nat. Med. 2006, 12:417-424.
49. Verweij M.C., et al. Inhibition of mouse TAP by immune evasion molecules encoded by non-murine herpesviruses. Mol. Immunol. 2011, 48:835-845.
50. Verweij M.C., et al. Structural and functional analysis of the TAP-inhibiting UL49.5 proteins of varicelloviruses. Mol. Immunol. 2011, 48:2038-2051.
51. Wang Y., et al. E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models. Nat. Biotechnol. 2003, 21:1328-1335.
52. Wei H., Wang Y., Chowdhury S.I. Bovine herpesvirus type 1 (BHV-1) UL49.5 luminal domain residues 30 to 32 are critical for MHC-I down-regulation in virus-infected cells. PLoS One 2011, 6:e25742.
53. York I., et al. A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes. Cell 1994, 77:525-535.
54. Zamarin D., et al. Enhancement of oncolytic properties of recombinant Newcastle disease virus through antagonism of cellular innate immune responses. Mol. Ther. 2009, 17:697-706.
55. Zamarin D., Holmgaard R.B., Subudhi S.K., Park J.S., Mansour M., Palese P., Merghoub T., Wolchok J.D., Allison J.P. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci. Transl. Med. 2014, 6:226ra32.